U.S. Tobacco Stock News

If you are wondering whether Bel Fuse shares still offer value after a strong run, this article explains what the current price might be implying about the business. The stock closed at US$172.94 recently, with a 7 day return of an 18.4% decline and a 30 day return of a 16.0% decline, while the 1 year return sits at 119.7% and the 3 year return is very large. These price moves sit against a backdrop of ongoing attention on Bel Fuse within the tech sector, as investors reassess companies that...

Bio-Techne recently presented at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at the Boston Marriott Copley Place Hotel in Boston, Massachusetts, sharing its latest updates with investors and industry participants. This conference appearance came shortly after broader healthcare sector concerns tied to a weak February jobs report, linking Bio-Techne’s story more closely to macroeconomic sentiment than to company-specific developments. We’ll now examine how sector-wide...

If you are wondering whether Microsoft is still fairly priced after its long run as a market heavyweight, looking closely at its current valuation can help you decide how it might fit into your portfolio. The stock last closed at US$408.96, with returns of 2.6% over the past 7 days, 1.9% over the past 30 days, a year-to-date return of a 13.5% decline, and 8.4% over the past year. The 3-year and 5-year returns sit at 64.9% and 81.5% respectively. Recent headlines around Microsoft have focused...

In early March 2026, Kennametal faced pressure after a weaker-than-expected U.S. February jobs report showed the manufacturing sector losing 12,000 positions, raising concerns about softer industrial activity. This macro shock matters because Kennametal’s tools and materials are closely tied to manufacturing demand, making labor-market softness a key watchpoint for its outlook. Against this backdrop of softer manufacturing employment, we’ll now examine how the latest data may influence...

In recent weeks, Badger Meter has faced cautious analyst sentiment ahead of an upcoming earnings release that is expected to show year-over-year EPS decline despite higher revenue, alongside insider share sales by senior executives Fred Begale and Kimberly Stoll over the past year. This combination of softer earnings expectations, premium valuation concerns, and ongoing insider selling has sharpened investor focus on how durable Badger Meter’s growth and profitability thesis really is. Now...

On February 24, 2026, Brady Corporation’s board declared a US$0.245 per-share dividend on Class A common stock, payable April 30, 2026, to shareholders of record as of April 9, 2026. This dividend decision comes alongside multi-year growth in sales, earnings, and free cash flow, underscoring Brady’s capacity to return cash to investors. We’ll now examine how Brady’s dividend declaration, against a backdrop of solid multi-year earnings and cash flow growth, influences its investment...

Mirum Pharmaceuticals (MIRM) is back in focus after the company completed enrollment for its Phase 3 AZURE-1 trial and finished screening for the Phase 3 AZURE-4 study of brelovitug in chronic hepatitis delta virus. See our latest analysis for Mirum Pharmaceuticals. The brelovitug trial milestones come after a busy few weeks that included Mirum’s fourth quarter and full year 2025 results, a shelf registration filing and a high profile appearance at a major healthcare conference. Despite a...

Dividend affirmation amid sectorwide credit jitters TriCo Bancshares (TCBK) recently declared a quarterly cash dividend of $0.36 per share, even as regional bank stocks, including TriCo, have come under pressure from concerns around private credit exposures. The dividend, payable on March 20, 2026 to shareholders of record on March 6, 2026, is the company’s 146th consecutive quarterly cash distribution to investors. See our latest analysis for TriCo Bancshares. TriCo’s recent dividend...

Vericel (VCEL) is back in focus after the FDA approved commercial manufacturing of its MACI cartilage repair therapy at the company’s Burlington, Massachusetts facility, a milestone tied directly to future production capacity. See our latest analysis for Vericel. Even with the FDA clearance for MACI manufacturing and recent earnings and guidance updates, Vericel’s share price has cooled, with a 1-year total shareholder return decline of 31.98%, although the 3-year total shareholder return of...

Recent trading in Huron Consulting Group (HURN) has drawn attention after a one-month return of about a 15% decline and a past three-month return of about a 15% decline, prompting closer scrutiny of its fundamentals. See our latest analysis for Huron Consulting Group. At a share price of $144.83, Huron’s recent 30 and 90 day share price returns of about a 15% decline sit in contrast with a 1 year total shareholder return of roughly a 3% decline and 3 and 5 year total shareholder returns of...

In a recent filing, Eva Live announced it secured $7 million in growth financing, another step closer to advancing the company’s broader investment narrative.

Recent share performance and business snapshot With no single headline event driving attention to Veris Residential (VRE), the recent share performance itself is the focus, as the stock shows double digit returns over the past month and past 3 months. Veris Residential is a real estate investment trust focused on Class A multifamily properties in the Northeast. It uses a technology enabled, vertically integrated platform to manage, operate, acquire, and develop its portfolio for residents and...

Corebridge Financial (CRBG) is back in focus after reporting a record US$41.7b in total premiums and deposits for 2025, alongside stronger capital and liquidity metrics that could influence how investors view the stock. See our latest analysis for Corebridge Financial. Despite the record premiums and deposits, Corebridge Financial’s recent share price performance has been weak, with a 30 day share price return of an 18.65% decline and a year to date share price return of a 16.53% decline,...

Alkermes plc recently reported that fourth‑quarter 2025 revenue slipped to US$384.55 million, with net income and earnings per share also lower year over year, while the Board confirmed CEO Richard Pops will retire in July 2026 and current COO Blair Jackson will assume the CEO role in August 2026. Alongside these results, Alkermes advanced its orexin agonist ALKS 2680 into Phase 3 trials for narcolepsy type 1, highlighting how its neuroscience pipeline is becoming increasingly central to the...

Certara recently highlighted that its Simcyp physiologically-based pharmacokinetic modeling was accepted by the U.S. FDA in place of multiple clinical pharmacology studies to support the new drug application for asciminib (Scemblix®), an allosteric BCR::ABL1 inhibitor for Chronic Myeloid Leukemia. This decade-long modeling effort, which replaced at least ten dedicated clinical studies and informed dosing and drug-interaction decisions, underscores how biosimulation can cut development costs...

Azenta (AZTA) has drawn attention after recent share price pressure, with the stock down about 27% year to date and roughly 44% over the past year. This has prompted investors to reassess its fundamentals. See our latest analysis for Azenta. The recent pressure on Azenta’s share price, including a 1-day share price return of negative 1.98% and a 30-day share price return of negative 15.39%, sits on top of a 1-year total shareholder return of negative 44.37%. This signals that momentum has...

What triggered fresh interest in Xeris Biopharma Holdings (XERS)? Xeris Biopharma Holdings (XERS) has drawn fresh attention after reporting fourth quarter and full year 2025 results that moved from loss to profit, paired with new 2026 revenue guidance and a US$40.7 million shelf registration filing. See our latest analysis for Xeris Biopharma Holdings. Despite Xeris Biopharma Holdings posting improved earnings and setting 2026 revenue guidance, recent share price returns have been weak, with...

MarketAxess Holdings Inc. recently appointed William Quan as Chief Technology Officer, tasking him with modernizing its global technology platforms and embedding AI and advanced data capabilities across the business. By bringing in a leader with deep experience in electronic trading and AI-driven platforms from firms like Amazon Web Services, J.P. Morgan, and Deutsche Bank, MarketAxess is signaling a stronger push to enhance its bond-trading technology and product innovation. With William...

In February 2026, Marqeta, Inc. reported fourth-quarter 2025 sales of US$172.11 million with sharply reduced net losses, issued 2026 guidance calling for double-digit net revenue and gross profit growth, and filed a US$106.08 million shelf registration for 25,935,338 Class A shares tied to an employee stock plan. This combination of improving financial results, clearer growth expectations, and a sizeable employee share offering highlights how Marqeta is balancing expansion with capital and...

In recent days, investor concerns about regional banks’ exposure to the opaque private credit market have weighed on The Bancorp, amid broader sector jitters following defaults and loan write-offs in that space. These worries come on top of earlier pressure from weaker quarterly results and a shrinking net interest margin, even as The Bancorp has built a niche in specialized fintech-focused banking and lending solutions. Next, we’ll examine how heightened worries about private credit...

In late February 2026, Starwood Property Trust, Inc. announced that its board had authorized a one-year share repurchase program of up to US$400 million, to be funded entirely from existing cash. This buyback authorization, following the company’s full-year 2025 results, signals a clear willingness to return capital while balancing earnings, leverage, and portfolio risk considerations. We’ll now examine how this sizable cash-funded buyback authorization may influence Starwood Property...

In February 2026, Xylem Inc. announced that its Board of Directors had approved a new share repurchase program, authorizing the company to buy back up to US$1.50 billion of its own stock with no expiration date. This move follows the completion of a prior authorization under which Xylem repurchased 5,200,000 shares for US$321.90 million, highlighting an ongoing preference for returning capital to shareholders alongside reinvestment in the business. We’ll now explore how this sizable,...

In late February 2026, SS&C Technologies Holdings, Inc. reported an 8.1% year-on-year revenue increase that exceeded analyst expectations and raised its full-year EPS and revenue guidance, citing strong execution and the breadth of its software and services portfolio. A few days earlier, SS&C announced a generative AI-powered sales enablement solution developed with Thornburg Investment Management, embedding advisor insights directly into CRM systems to streamline how asset managers prepare...

In early March 2026, Lincoln Electric Holdings’ shares came under pressure after EVP, CFO & Treasurer Gabriel Bruno sold 17,473 shares in an insider transaction, following earlier strong quarterly results and optimistic guidance. This combination of an executive share sale and upbeat analyst commentary has sharpened investor focus on how leadership actions align with the company’s longer-term outlook and fundamentals. We’ll now examine how the CFO’s recent insider sale could influence...